My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
From Revelation Biosciences, Inc.
Via Business Wire
Tickers REVB
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
From Revelation Biosciences, Inc.
Via GlobeNewswire
Tickers REVB REVBW
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.
From Revelation Biosciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.